Scientists map the genetic secrets of a rare brain cancer to pave the way for smarter treatments
NCT ID NCT07147751
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study examines tumor samples from 100 people diagnosed with primary central nervous system diffuse large B-cell lymphoma (PCNS-DLBCL), a rare cancer that starts in the brain or spine. Researchers will use advanced genetic and molecular techniques to identify patterns in the tumor's DNA, RNA, and other markers. The goal is to better understand how this cancer develops and survives, which could eventually lead to more personalized and effective treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this research could identify biological markers that help doctors choose more personalized therapies for this rare brain lymphoma.
- What could go wrong
- This is an observational study, not a treatment trial. It will not directly test any new drug or therapy, and findings may not immediately change patient care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM DIFFUSE LARGE B CELL LYMPHOMA (PCNS-DLBCL) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fondazione IRCCS Policlinico San Matteo Pavia
Pavia, 27100, Italy
-
Oncology Institute of Southern Switzerland and Institute of Oncology Research
Bellinzona, 6500, Switzerland